SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after delivering exceptional financial results that paradoxically led to a notable stock decline, sparking community debate over market manipulation, "sell the news" reactions, and the sustainability of AI-driven demand across the broader tech sector.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is trending after a substantial earnings miss and weak guidance led to a significant stock drop, causing widespread community distrust in management, though some investors see it as an oversold opportunity in the growing energy storage sector.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings (CELH) is trending after a strong Q4 earnings beat and optimistic statements from its CEO at the CAGNY conference regarding significant shelf space expansion for Celsius and Alani Nu. Community discussion reflects bullish enthusiasm for market share growth and potential PepsiCo buyout, yet also includes sharp criticism of the CEO and frustration over price volatility driven by profit-taking and broader market weakness.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is surging following better-than-expected financial results, reporting a surprise Q4 profit and raising revenue guidance, signaling a significant operational turnaround. The community is buzzing about new oncology and expanded infectious disease agreements leveraging its Matrix-M adjuvant technology, which combined with high short interest, is fueling strong short squeeze sentiment and excitement for future partnerships.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending after reporting strong quarterly financial results and significant share repurchases, yet community sentiment remains divided as the stock's price reaction is muted, fueling frustration over management's communication and ongoing speculation about the AUR200 pipeline and a potential buyout.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a hot topic as it approaches its anticipated earnings report, with strong community discussion around its expanding agentic AI platform, new global innovation hub, and recent Sales Assist launch driving expectations for significant revenue growth. The potential for profitability and high short interest are further fueling investor attention, as many anticipate a notable market reaction to its results and forward guidance.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is experiencing extreme volatility as federal approval to restart its Santa Ynez pipeline clashes with ongoing lawsuits from California environmental groups and the state. The community fiercely debates whether federal preemption will lead to a significant short squeeze or if persistent regulatory hurdles, a recent stock offering, and an ongoing SEC investigation will ultimately hinder operations.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is surging following its strong Q4 revenue beat, raised 2026 guidance, and major contract awards like the $151 billion SHIELD defense program, fueling intense community debate between bullish investors anticipating a short squeeze and skeptics highlighting ongoing losses and high valuation.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is at the center of investor discussion following its recent earnings, which highlighted a stable balance sheet and international growth amidst persistent challenges for its BetterHelp segment. This has polarized the community, with bulls seeing a deeply undervalued stock ready for a short squeeze, while bears remain skeptical of management's ability to drive sustained profitability in a competitive telehealth market.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending due to significant volatility following FDA feedback suggesting its Huntington's disease gene therapy, AMT-130, lacks sufficient Phase I/II data for accelerated approval. This has ignited fervent community discussion about the FDA's shifting regulatory landscape and whether recent critical comments were even directed at QURE, as the company prepares for a crucial Type A meeting to determine a path forward.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results

Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results Nuvalent Outlines Recent Pipeline Progress...

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Key PointsCommodore Capital reduced its Nuvalent stake by 850,000 shares in the fourth quarter; the estimated trade size was $83.81 million based on quarterly average pricing...

Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) has been given an average rating of "Moderate Buy" by the sixteen analysts that are covering the stock, MarketBeat reports. One investment analyst has...

Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans

Nuvalent (NASDAQ:NUVL) executives highlighted ongoing regulatory milestones for the company's lead oncology programs and discussed commercialization strategy, pipeline plans, and financial...

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PR Newswire CAMBRIDGE, Mass., Feb. 5...

Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) have earned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports...

Deborah Ann Miller Sells 700 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 700 shares of the company's stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an...

Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 14,300 Shares of Stock

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 14,300 shares of the business's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an...

Nuvalent (NASDAQ:NUVL) Reaches New 52-Week High - Here's Why

Nuvalent (NASDAQ:NUVL) Hits New 1-Year High - Should You Buy...

SG Americas Securities LLC Takes Position in Nuvalent, Inc. $NUVL

SG Americas Securities LLC purchased a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the...

$NUVL Q4 &#39;25 Earnings Results &amp; Recap

Nuvalent expects cash, cash equivalents, and marketable securities of $1.4 billion as of December 31, 2025, to fund operations into 2029, but may require additional capital to complete product development and commercialization. Nuvalent plans a potential U.S. commercial launch of zidesamtinib in 2026.

Stocktwits

Nuvalent Inc - Ordinary Shares - Class A

 Q4 '25 Earnings Results & Recap

Nuvalent expects cash, cash equivalents, and marketable securities of $1.4 billion as of December 31, 2025, to fund operations into 2029, but may require additional capital to complete product development and commercialization. Nuvalent plans a potential U.S. commercial launch of zidesamtinib in 2026.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Current Price	$103.00
Prev Close	$104.53
Open	$105.69
Dividend Yield	0.00%
50-Day Moving Average	$103.52
Beta	1.17
Avg. Volume	588,558.30
PE Ratio	-19.66

52-Week High	$113.02
52-Week Low	$55.54
Market Capitalization	$7.6B
EPS (Annual)	-$3.93
Price to Book	8.94
Revenue Per Employee	$0.00

NUVL
Nuvalent Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NUVL News

NUVLNuvalent Inc - Ordinary Shares - Class A